Insilico (03696) has announced that the group has entered into a strategic drug development collaboration with CMS. Under this partnership, the two companies will engage in a series of AI-enabled innovative drug development projects targeting the central nervous system and autoimmune diseases. According to the agreement, they will combine Insilico's validated AI platform and AI-driven drug discovery capabilities with CMS's experienced R&D team and deep understanding of disease areas to jointly advance the collaborative development of no fewer than two R&D projects. Additionally, Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project.